Wilmington, NC and Memphis, TN,February 3, 2000–PPD, Inc. (Nasdaq: PPDI) and CancerConsultants.com, Inc., an Internet-based cancer information products company, announced today an exclusive service agreement between the two Companies.

CancerConsultants.com (CC.com) operates and markets oncology Internet products designed to promote access to clinical trials, educate cancer patients and their families about various cancer treatments, and perform market research. The company currently has four products respectively providing comprehensive cancer treatment information, promoting specialized cancer treatment provider services, facilitating patient recruitment to clinical trials, and providing market research programs based on rapid data collection from targeted physicians and patients.

In the exclusive arrangement, CC.com will include information on clinical trials being managed by PPD on its daily-updated 411Cancer.com™ and eCancerTrials.com™ web sites and will manage an online patient recruitment program to facilitate rapid enrollment into PPD’s clinical trials. The Internet-based company is also developing and managing an online investigator recruitment and registration program to further PPD’s strong network of oncologists with experience in conducting clinical trials in the United States. In addition, the CC.com market research web site, Oncosurvey.com™, is being developed with PPD to include and maintain an online protocol survey system with a 72-hour turnaround to evaluate protocol feasibility and site identification. This site has already been used for product launch initiatives, promotional testing and in licensing.

"Combining our infomediary programs with PPD allows us to expand our services and reach," stated Charles Weaver, M.D., founder and chief executive officer at CC.com. "As PPD has many relationships with pharmaceutical and biotechnology companies, we will be able to offer a wide range of online solutions, oncology services and support for their existing and new customers. The overall goal is to improve access to cancer information and services for benefit to the patient.

As per the agreement, PPD is the only development services provider (CRO) to which CC.com will provide its products and services. CC.com will continue to have and obtain service arrangements with cancer treatment providers at hospital-based cancer centers and physician oncology practices, cancer treatment institutions and biopharmaceutical companies. CC.com currently promotes its services through physician practices, healthcare organizations, patient advocacy groups and through an advertising agreement with America-On-Line (AOL).

"This impressive infomediary will help us support our customers and cancer treatment providers in getting accurate and detailed information about treatment options and services to patients at the time when important personal decisions are being made," stated Fred Eshelman, chief executive officer at PPD. "We believe this is an excellent addition to the services provided by the PPD Oncology Division and it serves to further support our corporate Internet strategy."

CancerConsultants.com (CC.com) operates and markets business-to-business and business-to-consumer internet solutions for providers of cancer services through its web sites: 411Cancer.com, providing comprehensive cancer treatment information; 911Cancer.com, helping providers promote specialized cancer treatment services; eCancerTrials.com, facilitating online recruitment of patients to cancer clinical trials; and Oncosurvey.com, a market research program based on rapid data collection from targeted physicians and patients.

PPD, Inc. (Nasdaq: PPDI) is a leading global provider of contract and consulting research and development services for pharmaceutical and biotechnology companies. With a corporate mission to provide services that maximize the return on clients' R&D investments, PPD provides innovative technologies, therapeutic expertise and comprehensive services for drug discovery and pre-clinical programs, Phase I-IV clinical development and post-market support. The company employs more than 3,500 professionals in 47 offices in 19 countries around the world.

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions about the value and risk of this relationship to PPD, contained in the foregoing are forward-looking statements that involve a number of risks and uncertainties. Although PPD has used best efforts to be accurate in making those forward-looking statements, it is possible that the assumptions made by management may not materialize. In addition, other important factors which could cause results to differ materially include the following: economic conditions in the pharmaceutical and biotechnology industries; outsourcing trends in the pharmaceutical and biotechnology industries; risks associated with acquisitions; loss of large contracts; competition within the CRO and pharmaceutical industries; continued success in sales growth; the ability to attract and retain key personnel; and the risk factors set forth from time to time in the SEC filings for PPD, copies of which are available upon request from the PPD investor relations department.

Editor’s note: For more information on PPD, visit the company web site at www.ppdi.com. For more information on the products and services provided by CancerConsultants.com, visit the company web sites at www.411Cancer.com, www.911Cancer.com, www.eCancerTrials.com, www.Oncosurvey.com.